Key result
Avatrombopag yields comparable platelet elevation with or without CYP3A/CYP2C9 inhibitors.
Why the study?
Does avatrombopag require dose adjustment when co-administered with CYP3A and CYP2C9 inhibitors in patients with chronic liver disease?
Population
Patients with chronic liver disease (CLD) and thrombocytopenia
Comparison
Avatrombopag 40 and 60 mg for 5 days with… vs Avatrombopag without concomitant CYP3A and…
Design
Other
Follow-up
5 days
Authors
Loading...
May support no dose adjustment with CYP inhibitors in chronic liver disease; leaves open confirmation in larger trials.
Does avatrombopag require dose adjustment when co-administered with CYP3A and CYP2C9 inhibitors in patients with chronic liver disease?
Dose adjustment of avatrombopag is not necessary when co-administered with CYP3A and CYP2C9 inhibitors in patients with chronic liver disease due to comparable platelet count elevations and limited treatment duration.
Nomoto et al. (2018) studied Chronic liver disease with thrombocytopenia. Avatrombopag with concomitant CYP3A and CYP2C9 inhibitors vs. Avatrombopag without concomitant CYP3A and CYP2C9 inhibitors was evaluated on Platelet count elevation and pharmacokinetics. Avatrombopag 40 and 60 mg for 5 days showed comparable platelet elevation with and without CYP3A/CYP2C9 inhibitors, with <10% of patients exceeding 200×10^9/L platelets.